Inclusion Criteria:

- Subjects who the investigator believes that they can and will comply with the
requirements of the protocol.

- A female who enrolled in NCT00332475 and received three doses of GSK 580299 vaccine.

- Written informed consent obtained from the subject.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) or planned use
during the study period.

- Chronic administration (defined as more than 14 consecutive days) of
immunosuppressants or other immune-modifying drugs occurring less than three months
prior to blood sampling.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product (pharmaceutical product or device).

- Administration of immunoglobulins and/or any blood products within the three months
preceding blood sampling.

- Administration or planned administration of any HPV vaccine, other than the three
doses of HPV-16/18 vaccine administered in NCT00332475 study.